Cogent Biosciences, Inc. (COGT)

About Cogent Biosciences, Inc.

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

COGT passes 1 of our 30 screens today

Each screen prints the exact criteria it used, and the circumstances in which it is wrong.

Smart money ownership

10 of the funds we track reported a position in their latest SEC 13F filing. Largest first:

• D. E. Shaw, D. E. Shaw & Co., Inc.$71.91M · 0.0% of book
• Ken Griffin, CITADEL ADVISORS LLC$66.01M · 0.0% of book
• Marshall Wace, MARSHALL WACE, LLP$61.59M · 0.1% of book
• Steve Cohen, Point72 Asset Management, L.P.$54.30M · 0.1% of book
• Israel Englander, MILLENNIUM MANAGEMENT LLC$45.90M · 0.0% of book

A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.

Common questions